; (2) identify, for each of the active pharmaceutical ingredients and drugs that are identified under paragraph (1)— (A) the active pharmaceutical ingredients and drugs with vulnerable supply chains; (B) the amount manufactured by each establishment registered under section 510(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(b) ), as reported under section 510(j)(3) of such Act ( 21 U.S.C. 360(j)(3) ), or, with respect to any active pharmaceutical ingredient or drug for which such information is unavailable, an explanation for why the information is unavailable; (C) the drugs that are sourced either exclusively or primarily from foreign establishments, including drugs manufactured domestically from active pharmaceutical ingredients sourced exclusively or primarily from foreign establishments; and (D) the active pharmaceutical ingredients that are sourced either exclusively or primarily from foreign establishments; (3) assess key starting materials and excipients used in manufacturing the active pharmaceutical ingredients and drugs identified under paragraph (1); (4) assess current domestic manufacturing capabilities with respect to drugs (including key starting materials, excipients, and active pharmaceutical ingredients) identified under paragraph (1), including advanced manufacturing capabilities; (5) identify critical vulnerabilities, including cybersecurity threats; (6) identify the existing statutory authorities the Department of Defense, the Department of Health and Human Services, and the Department of Homeland Security have to address public health or national security risks that may arise as a result of vulnerabilities in the pharmaceutical supply chain